Pfizer PFE stock forecast 2025 aligns with sector-wide P/E averages of 12–14x; valuation upside hinges on management’s capital allocation efficiency and licensing agreements globally. Pfizer provided a TSR of 2.3% over the last twelve months. Unfortunately this falls short of the market return. But at least that's still a gain! Over five years the TSR has been a reduction of 0.4% per year, over five years. So this might be a sign the business has turned its fortunes around. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Pfizer is showing 2 warning signs in our investment analysis , you should know about... The transaction is expected to close in Q4 2025 , subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions. Institutional consensus for Pfizer PFE stock forecast 2025 expects stock volatility to remain moderate, driven more by clinical trial outcomes than broader economic cycles typical for diversified pharma.